General
Preferred name
ZOTIRACICLIB
Synonyms
TG-02 ()
TG02, TG-02 ()
SB-1317 ()
TG02 ()
SB1317, cmpd 26h ()
TG-02 hydrochloride ()
SB1317 hydrochloride (1204918-72-8(free base)) ()
SB1317 hydrochloride (937270-47-8(free base)) ()
TG-02 (SB1317) ()
(E/Z)-TG02 ()
(E/Z)-SB1317 ()
(E/Z)-TG02 (hydrochloride) ()
(E/Z)-SB1317 (hydrochloride) ()
(E/Z)-Zotiraciclib ()
(E/Z)-Zotiraciclib (hydrochloride) ()
SB1317 (TG02) ()
EX45 ()
EX 45 ()
SB1317 ()
SB-1317 FREE BASE ()
SB-1317 ()
P&D ID
PD012633
CAS
937270-47-8
1204918-72-8
1321626-25-8
Tags
available
drug candidate
Drug indication
Anaplastic astrocytoma
Recurrent glioblastoma
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Zotiraciclib (TG02) is an orally active multi-kinase inhibitor, with a unique activity profile against CDKs, JAK2 and FLT3 . Like it is a small molecule macrocycle. TG02 was rationally designed to simultaneously inhibit several key signalling pathways, with the aim of maximising anti-cancer efficacy. It is being investigated for its anti-leukemic potential .
The compound is administered as the citrate salt. (GtoPdb)
Cell lines
8
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
A11962
Cayman Chemical Bioactives
26817
CDK inhibitor database (CDKiDB)
ChEMBL Drugs
CHEMBL1944698
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB16656
DrugMAP
DMZFIGQ
EU-OPENSCREEN Bioactive Compound Library
EOS101788
Guide to Pharmacology
9095
JUMP-Target 1 Compound Set
16739650
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1944698
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1944698
MedChem Express Bioactive Compound Library
HY-15166
HY-15166A
ReFrame library
Selleckchem Bioactive Compound Library
sb1317-tg02
TargetMol Bioactive Compound Library
T4227
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
372.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
4
Aromatic Ring Count
3
cLogP
4.66
TPSA
50.28
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
18.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
CDK1,CDK2,CDK7,CDK9,JAK2,FLT3
Pathway
Angiogenesis
Cell Cycle/Checkpoint
Chromatin/Epigenetic
Tyrosine Kinase/Adaptors
JAK/STAT Signaling
Stem Cells
Cell Cycle/DNA Damage
Epigenetics
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Target
CDK2
FLT3
JAK2
CDK1, CDK2, CDK7, CDK9, FLT3, JAK2
CDK9
CDK
JAK
FLT3,JAK
MOA
CDK inhibitor
FLT inhibitor
JAK inhibitor
CDK inhibitor, FLT3 inhibitor, JAK inhibitor
Source data